Table 1. Dopaminergic and serotonergic ligands miscue regeneration.
| Class | Drug | Activity | Phenotype | [X], source |
| Neuropeptides | FMRFamide | agonist | - | 1 mM,1 |
| Neuropeptides | Spantide | antagonist | 100 µM,2 | |
| Adrenergic | Epinephrine | agonist | - | 5 mM,1 |
| Adrenergic | Norepinephrine | agonist | - | 5 mM,1 |
| Adrenergic | L-phenylephrine | agonist | - | 100 µM,1 |
| Adrenergic | Propranolol | antagonist | - | 10 µM,1 |
| GABAergic | GABA | agonist | - | 10 mM,1 |
| GABAergic | Piperazine | agonist | - | 1 mM,1 |
| GABAergic | Baclofen | agonist | - | 500 µM,1 |
| GABAergic | Carbamazepine | agonist | - | 250 µM,1 |
| Glutaminergic | L-glutamic acid | agonist | - | 500 µM,1 |
| Glutaminergic | NMDA | agonist | - | 1 mM,1 |
| Glutaminergic | AMPA | agonist | - | 1 mM,1 |
| Glutaminergic | Topiramate | antagonist | - | 10 µM,1 |
| Cholinergic | Acetylcholine | agonist | - | 1 mM,1 |
| Cholinergic | Nicotine | agonist | - | 1 mM,1 |
| Cholinergic | Levamisole | agonist | 2-head (7%) | 100 µM, 1 |
| Cholinergic | Muscarine | agonist | - | 100 µM,1 |
| Cholinergic | Atropine | antagonist | - | 500 µM,1 |
| Cholinergic | Tubocurarine | antagonist | - | 100 µM,1 |
| Cholinergic | α-Bungarotoxin | antagonist | - | 10 µM,3 |
| Biogenic amines | Octopamine | agonist | - | 10 mM,1 |
| Biogenic amines | Tyramine | agonist | - | 100 µM,1 |
| Biogenic amines | Histamine | agonist | - | 5 mM,1 |
| Dopaminergic | Bromocriptine | agonist | 2-head (64%) | 2 µM, 1 |
| Dopaminergic | Dopamine | agonist | 2-head (5%) | 500 µM, 1 |
| Dopaminergic | Apomorphine | agonist | 2-head (4%) | 750 nM, 1 |
| Dopaminergic | Haloperidol | antagonist | 2-head (5%), no-head (4%) | 5 µM, 1 |
| Dopaminergic | Bupropion | DAT antagonist | 2-head (10%) | 1 µM, 1 |
| Dopaminergic | SKF 38393 | agonist | 2-head (4%) | 50 µM, 1 |
| Dopaminergic | Trifluoperazine | antagonist | 2-head (15%) | 10 µM, 1 |
| Dopaminergic | Pergolide | agonist | - | 100 µM,1 |
| Dopaminergic | Ropinirole | agonist | - | 100 µM,1 |
| Dopaminergic | SCH 23390 | antagonist | - | 10 µM,1 |
| Dopaminergic | ±Sulpiride | antagonist | - | 250 µM,1 |
| Dopaminergic | GBR 12909 | DAT antagonist | - | 1 µM,1 |
| Serotonergic | 5HT | agonist | No-head (17%) | 1 mM, 1 |
| Serotonergic | 8-OH DPAT | agonist | No-head (20%) | 10 µM, 1 |
| Serotonergic | Fluoxetine | SSRI | No-head (5%) | 2 µM, 1 |
| Serotonergic | Mianserin | antagonist | 2-head (6%) | 10 µM, 1 |
| Serotonergic | m-CPP | agonist | - | 10 µM,1 |
| Multiple targets | Reserpine | 2-head (7.5%) | 10 µM, 1 | |
| Multiple targets | Amitriptyline | 2-head (3%) | 7.5 µM, 1 | |
| Multiple targets | Pindolol | 2-head (3%) | 200 µM, 2 | |
| Multiple targets | Bafilomycin A1 | 2-head (3%) | 10 nM, 1 | |
| Multiple targets | Lobeline | 2-head (3%), no-head (3%) | 7.5 µM, 1 | |
| Multiple targets | Clozapine | 2-head (5%) | 1 µM, 1 |
Results from pharmacological screen investigating the impact of different agents that modify neurotransmission on planarian regenerative polarity. Each ligand within the different classes was tested up to the indicated concentration after first performing toxicity assays to identify the concentration range over which worm viability was unaffected. In each test, drug exposure was for one day using cohorts of n≥30 worms for n = 3 trials. A lack of effect in regenerative polarity is indicated by ‘-’, whereas polarity defects (phenotype and penetrance) are described. Drugs were sourced as follows:
1
Sigma Aldrich,
2
Tocris Bioscience,
3
Invitrogen.